Počet záznamů: 1

Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats

  1. 1.
    0474019 - FGU-C 2018 RIV US eng J - Článek v odborném periodiku
    Sedláková, L. - Čertíková - Chábová, V. - Doleželová, Š. - Škaroupková, P. - Kopkan, L. - Husková, Z. - Červenková, L. - Kikerlová, S. - Vaněčková, Ivana - Sadowski, J. - Kompanowska - Jezierska, E. - Kujal, P. - Kramer, H. J. - Červenka, L.
    Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.
    Clinical and Experimental Hypertension. Roč. 39, č. 2 (2017), s. 183-195 ISSN 1064-1963
    Institucionální podpora: RVO:67985823
    Klíčová slova: chronic kidney disease * endothelin system * hypertension * renin–angiotensin system * 5/6 nephrectomy
    Kód oboru RIV: FA - Kardiovaskulární nemoci vč. kardiochirurgie
    Impakt faktor: 1.162, rok: 2016

    Early addition of endothelin (ET) type A (ETA) receptor blockade to complex renin–angiotensin system (RAS) blockade has previously been shown to provide better renoprotection against progression of chronic kidney disease (CKD) in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX). In this study, we examined if additional protection is provided when ETA blockade is applied in rats with already developed CKD. Methods: For complex RAS inhibition, an angiotensin-converting enzyme inhibitor along with angiotensin II type 1 receptor blocker was used. Alternatively, ETA receptor blocker was added to the RAS blockade. The treatments were initiated 6 weeks after 5/6 NX and the follow-up period was 50 weeks. Results: When applied in established CKD, addition of ETA receptor blockade to the complex RAS blockade brought no further improvement of the survival rate (30% in both groups); surprisingly, aggravated albuminuria (588 ± 47 vs. 245 ± 38 mg/24 h, p < 0.05) did not reduce renal glomerular injury index (1.25 ± 0.29 vs. 1.44 ± 0.26), did not prevent the decrease in creatinine clearance (203 ± 21 vs. 253 ± 17 µl/min/100 g body weight), and did not attenuate cardiac hypertrophy to a greater extent than observed in 5/6 NX TGR treated with complex RAS blockade alone. Conclusions: When applied in the advanced phase of CKD, addition of ETA receptor blockade to the complex RAS blockade brings no further beneficial renoprotective effects on the CKD progression in 5/6 NX TGR, in addition to those seen with RAS blockade alone.
    Trvalý link: http://hdl.handle.net/11104/0271115